Clinical trial
Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small…
NCT00290017 · Point Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00290017 |
|---|---|
| Title | Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy |
| Official title | A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed vs. Pemetrexed and Placebo in Patients With Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy |
| Lead sponsor | Point Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung, Lung Cancer, Neoplasms, Lung, Pulmonary |
| Intervention type | Drug |
| Interventions | talabostat, pemetrexed |
| Enrollment | 400 |
| Start date | Feb 1, 2006 |
| First posted | Feb 10, 2006 |
| Last update posted | Jun 8, 2007 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: